What Are Breast Neoplasms?

Breast neoplasms are abnormal growths of tissue in the breast resulting from uncontrolled cell proliferation, and they encompass a wide spectrum from entirely benign masses to invasive cancers. The term neoplasm is broader than cancer: it includes all new tissue formations, regardless of whether they are locally invasive or capable of metastasis. In clinical and biomedical engineering practice, classifying a breast neoplasm accurately, whether benign or malignant, and identifying its tissue origin and grade, drives all subsequent imaging, biopsy, and treatment decisions. Breast neoplasms arise from epithelial, stromal, or other mammary tissue components, and their classification reflects both the cell type of origin and the degree of architectural disruption relative to normal breast tissue.

The study of breast neoplasms draws on pathology, medical imaging, molecular biology, and biomedical engineering. Accurate characterization depends on histopathological examination of tissue samples, with imaging playing a triage and guidance role before tissue is obtained.

Benign Breast Neoplasms

Benign breast neoplasms are the most common type of breast mass encountered clinically. Fibroadenoma is the most prevalent benign tumor of the breast, accounting for approximately 68% of breast masses in large case series and most common in women under 35. A fibroadenoma is a fibroepithelial lesion driven by the stromal component and typically presents as a firm, mobile, well-circumscribed mass on imaging. Papillomas, lipomas, and hamartomas are among the other benign neoplastic entities. The significance of benign neoplasms lies partly in their imaging appearance, which can overlap with malignancy, and partly in their association with subsequent risk. Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), while not neoplasms in the strict sense, are proliferative lesions that increase lifetime breast cancer risk by approximately four-fold according to long-term follow-up studies reviewed at PMC on histopathological analysis of breast carcinoma.

Malignant Breast Neoplasms

Malignant breast neoplasms range from in situ lesions confined to ducts or lobules to invasive carcinomas capable of lymph node involvement and distant metastasis. Ductal carcinoma in situ (DCIS) is the most common in situ malignancy; cells proliferate abnormally within the ducts but have not penetrated the basement membrane. DCIS is categorized by nuclear grade and comedonecrosis pattern, as these features predict the likelihood of progression to invasive disease. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most common invasive subtypes, together accounting for over 90% of breast cancer diagnoses. Molecular classification by hormone receptor and HER2 expression further subdivides invasive carcinomas into subtypes with distinct prognoses and treatment responses, as detailed in the PMC review Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance.

Imaging and Computational Analysis of Neoplasms

Breast imaging systems are designed and evaluated primarily around their ability to distinguish benign from malignant neoplasms while minimizing both false-positive recalls and false-negative misses. Mammographic features such as mass shape, margin, and density, as well as the presence of microcalcifications, are encoded in the ACR Breast Imaging Reporting and Data System (BI-RADS) lexicon, a standardized vocabulary that maps imaging descriptors to clinical action categories. Computational pathology approaches apply deep learning to whole-slide histopathological images to automate grading and subtype classification. A review of breast histopathological image analysis using image processing techniques published in PMC outlines how convolutional network architectures have been adapted for mitosis detection, nuclear segmentation, and tissue-level classification in breast pathology workflows.

Applications

Research and clinical practice around breast neoplasms supports a range of applications, including:

• Radiological screening and BI-RADS classification for population-level cancer detection
• Automated pathology slide analysis for grading and subtype assignment
• Risk modeling using neoplasm history to guide screening intervals and chemoprevention
• Surgical margin assessment in lumpectomy for in situ and invasive disease
• Molecular profiling for selection of targeted and immunotherapy regimens